MA51287A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51287A MA51287A MA051287A MA51287A MA51287A MA 51287 A MA51287 A MA 51287A MA 051287 A MA051287 A MA 051287A MA 51287 A MA51287 A MA 51287A MA 51287 A MA51287 A MA 51287A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Details Of Garments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608644P | 2017-12-21 | 2017-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51287A true MA51287A (fr) | 2021-03-31 |
Family
ID=65003515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051287A MA51287A (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11834486B2 (fr) |
| EP (1) | EP3727425A1 (fr) |
| JP (2) | JP6987993B2 (fr) |
| KR (1) | KR102440323B1 (fr) |
| CN (1) | CN111511387A (fr) |
| AR (1) | AR113487A1 (fr) |
| AU (1) | AU2018388895B2 (fr) |
| BR (1) | BR112020010410A2 (fr) |
| CA (1) | CA3084004C (fr) |
| CL (1) | CL2020001636A1 (fr) |
| CO (1) | CO2020006253A2 (fr) |
| CR (1) | CR20200256A (fr) |
| DO (1) | DOP2020000124A (fr) |
| EA (1) | EA202091284A1 (fr) |
| EC (1) | ECSP20032306A (fr) |
| IL (2) | IL325352A (fr) |
| JO (1) | JOP20200136B1 (fr) |
| MA (1) | MA51287A (fr) |
| MX (2) | MX2020006547A (fr) |
| MY (1) | MY199545A (fr) |
| PE (1) | PE20200926A1 (fr) |
| PH (1) | PH12020551024A1 (fr) |
| SG (1) | SG11202004359YA (fr) |
| TW (2) | TWI810937B (fr) |
| UA (1) | UA127589C2 (fr) |
| WO (1) | WO2019125929A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| ES3068975T3 (en) * | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| WO2021034815A1 (fr) * | 2019-08-19 | 2021-02-25 | Eli Lilly And Company | Procédés de fabrication d'analogues d'incrétine |
| AR120714A1 (es) | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| CA3165430A1 (fr) * | 2020-01-23 | 2021-07-29 | Jorge Alsina-Fernandez | Composes co-agonistes de gip/glp1 |
| US20230310630A1 (en) * | 2020-07-17 | 2023-10-05 | Hanmi Pharm. Co., Ltd. | Therapeutic use of combination comprising triple agonistic long-acting conjugate or triple agonist |
| JP2023537895A (ja) * | 2020-08-14 | 2023-09-06 | ハンミ ファーマシューティカル カンパニー リミテッド | 三重活性体持続型結合体を有効成分として含む薬学組成物 |
| WO2022090447A1 (fr) | 2020-10-30 | 2022-05-05 | Novo Nordisk A/S | Agonistes triples du récepteur de glp-1, gip et glucagon |
| TW202423476A (zh) | 2021-03-23 | 2024-06-16 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| CA3219647A1 (fr) * | 2021-05-26 | 2022-12-01 | The United Bio-Technology (Hengqin) Co., Ltd. | Multiagonistes et utilisation connexe |
| WO2022268029A1 (fr) * | 2021-06-21 | 2022-12-29 | 广东东阳光药业有限公司 | Agoniste triple pour récepteurs glp-1, gcg et gip |
| AU2022298662B2 (en) | 2021-06-23 | 2025-06-05 | Eli Lilly And Company | An incretin analog for use in glycemic control and weight management |
| KR20240099485A (ko) * | 2021-11-19 | 2024-06-28 | 메드샤인 디스커버리 아이엔씨. | 스테이플화 펩타이드 및 이의 용도 |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN117417411B (zh) * | 2022-09-28 | 2025-08-29 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| AU2024215381A1 (en) | 2023-01-31 | 2025-09-18 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| WO2024213022A1 (fr) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | Analogues d'incrétine et leur procédé de préparation, et utilisation |
| CN120329412A (zh) * | 2023-11-06 | 2025-07-18 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| CN120349393A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| CN119241684B (zh) * | 2024-11-22 | 2025-02-25 | 徐州医科大学 | 一种肠促胰岛素类似物及其用途 |
| GB202418179D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
| GB202418172D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8779103B2 (en) | 2009-03-27 | 2014-07-15 | Glaxo Group Limited | Drug fusions and conjugates |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| AU2014345570B2 (en) * | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| CA2929459C (fr) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Composes agonistes doubles de gip et glp-1 et procedes associes |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| TWI783244B (zh) | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2018
- 2018-12-05 TW TW111118551A patent/TWI810937B/zh active
- 2018-12-05 TW TW107143623A patent/TWI767095B/zh active
- 2018-12-06 AR ARP180103573A patent/AR113487A1/es unknown
- 2018-12-14 SG SG11202004359YA patent/SG11202004359YA/en unknown
- 2018-12-14 EP EP18830614.6A patent/EP3727425A1/fr active Pending
- 2018-12-14 IL IL325352A patent/IL325352A/en unknown
- 2018-12-14 EA EA202091284A patent/EA202091284A1/ru unknown
- 2018-12-14 CN CN201880082714.8A patent/CN111511387A/zh active Pending
- 2018-12-14 MY MYPI2020003206A patent/MY199545A/en unknown
- 2018-12-14 MX MX2020006547A patent/MX2020006547A/es unknown
- 2018-12-14 AU AU2018388895A patent/AU2018388895B2/en active Active
- 2018-12-14 BR BR112020010410-8A patent/BR112020010410A2/pt unknown
- 2018-12-14 PE PE2020000800A patent/PE20200926A1/es unknown
- 2018-12-14 US US16/769,015 patent/US11834486B2/en active Active
- 2018-12-14 IL IL275469A patent/IL275469B2/en unknown
- 2018-12-14 JP JP2020532952A patent/JP6987993B2/ja active Active
- 2018-12-14 MA MA051287A patent/MA51287A/fr unknown
- 2018-12-14 WO PCT/US2018/065605 patent/WO2019125929A1/fr not_active Ceased
- 2018-12-14 CA CA3084004A patent/CA3084004C/fr active Active
- 2018-12-14 UA UAA202002893A patent/UA127589C2/uk unknown
- 2018-12-14 CR CR20200256A patent/CR20200256A/es unknown
- 2018-12-14 KR KR1020207017385A patent/KR102440323B1/ko active Active
-
2020
- 2020-05-22 CO CONC2020/0006253A patent/CO2020006253A2/es unknown
- 2020-06-02 JO JOJO/P/2020/0136A patent/JOP20200136B1/ar active
- 2020-06-17 PH PH12020551024A patent/PH12020551024A1/en unknown
- 2020-06-17 CL CL2020001636A patent/CL2020001636A1/es unknown
- 2020-06-17 DO DO2020000124A patent/DOP2020000124A/es unknown
- 2020-06-19 EC ECSENADI202032306A patent/ECSP20032306A/es unknown
- 2020-07-13 MX MX2025003745A patent/MX2025003745A/es unknown
-
2021
- 2021-12-01 JP JP2021195036A patent/JP2022043082A/ja not_active Withdrawn
-
2023
- 2023-10-30 US US18/497,390 patent/US20240190936A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3817822A4 (fr) | Agents de dégradation de protéines et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3445365A4 (fr) | Inhibiteurs d'ezh2 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3749314A4 (fr) | Méthotrexate alpha-polyglutamaté et utilisations associées | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| EP2968443A4 (fr) | Analogues d'hepcidine et leurs utilisations | |
| EP3439741A4 (fr) | Antagonistes d'alk7 et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations |